SG11201408107RA - Method for quantifying immune cells in tumoral tissues and its applications - Google Patents

Method for quantifying immune cells in tumoral tissues and its applications

Info

Publication number
SG11201408107RA
SG11201408107RA SG11201408107RA SG11201408107RA SG11201408107RA SG 11201408107R A SG11201408107R A SG 11201408107RA SG 11201408107R A SG11201408107R A SG 11201408107RA SG 11201408107R A SG11201408107R A SG 11201408107RA SG 11201408107R A SG11201408107R A SG 11201408107RA
Authority
SG
Singapore
Prior art keywords
paris
rue
international
immune cells
medecine
Prior art date
Application number
SG11201408107RA
Other languages
English (en)
Inventor
Jérôme Galon
Franck Pagès
Bernhard Mlecnik
Original Assignee
Inserm Inst Nat De La Santé Et De La Rech Médicale
Univ Paris Descartes
Assist Publ Hopitaux De Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inserm Inst Nat De La Santé Et De La Rech Médicale, Univ Paris Descartes, Assist Publ Hopitaux De Paris filed Critical Inserm Inst Nat De La Santé Et De La Rech Médicale
Publication of SG11201408107RA publication Critical patent/SG11201408107RA/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG11201408107RA 2012-06-14 2013-06-14 Method for quantifying immune cells in tumoral tissues and its applications SG11201408107RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2012001446 2012-06-14
PCT/EP2013/062405 WO2013186374A1 (en) 2012-06-14 2013-06-14 Method for quantifying immune cells in tumoral tissues and its applications

Publications (1)

Publication Number Publication Date
SG11201408107RA true SG11201408107RA (en) 2015-01-29

Family

ID=46881097

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201408107RA SG11201408107RA (en) 2012-06-14 2013-06-14 Method for quantifying immune cells in tumoral tissues and its applications

Country Status (13)

Country Link
US (1) US10317408B2 (https=)
EP (1) EP2861986B1 (https=)
JP (1) JP6449765B2 (https=)
KR (1) KR102179848B1 (https=)
CN (1) CN104541167B (https=)
AU (1) AU2013276470B2 (https=)
BR (1) BR112014031143B8 (https=)
CA (1) CA2873278C (https=)
DE (1) DE13731071T1 (https=)
ES (1) ES2902879T3 (https=)
IL (1) IL235738B (https=)
SG (1) SG11201408107RA (https=)
WO (1) WO2013186374A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6605506B2 (ja) 2014-02-24 2019-11-13 ヴェンタナ メディカル システムズ, インク. CD3、CD8、CD20及びFoxP3の同時検出によりがんに対する免疫応答をスコア化するための方法、キット、及びシステム
EP3195191B1 (en) * 2014-09-03 2020-10-21 Ventana Medical Systems, Inc. Systems and methods for calculating immune scores
WO2016073760A1 (en) * 2014-11-05 2016-05-12 The Regents Of The University Of California Methods for stratifying non-responders to therapies that block pd1/pdl1 axis
CA2973878A1 (en) 2015-01-22 2016-07-28 University Of Massachusetts Cancer immunotherapy
US10705088B2 (en) * 2015-10-23 2020-07-07 Novartis Ag Method of scoring a sample comprising tumor tissue
US20190309369A1 (en) * 2016-05-09 2019-10-10 Inserm (Institute National De La Sante Et De La Recherche Medicale) Methods for classifying patients with a solid cancer
EP3459046B1 (en) * 2016-05-18 2021-06-16 F. Hoffmann-La Roche AG Tumor proximity measure
US12158399B2 (en) * 2016-08-05 2024-12-03 Duke University CaMKK2 inhibitor compositions and methods of using the same
US11048911B2 (en) * 2016-10-27 2021-06-29 Koninklijke Philips N.V. Apparatus for determining cellular composition information in one or more tissue samples
CA3037046A1 (en) 2016-10-31 2018-05-03 University Of Massachusetts Targeting microrna-101-3p in cancer therapy
CN106846310A (zh) * 2017-01-19 2017-06-13 宁波江丰生物信息技术有限公司 一种基于免疫组化技术的病理辅助分析方法
EP3659110A1 (en) * 2017-07-24 2020-06-03 Ventana Medical Systems, Inc. Methods and systems for evaluation of immune cell infiltrate in tumor samples
US11814623B2 (en) 2018-01-30 2023-11-14 University Of Massachusetts Methods of treating a wound using epigenetic regulation
DK3746790T3 (da) 2018-01-31 2023-12-11 Ventana Med Syst Inc Fremgangsmåder og systemer til evaluering af immuncelleinfiltrat i kolorektal stadie III cancer
EP3921648A1 (en) * 2019-02-05 2021-12-15 Ventana Medical Systems, Inc. Methods and systems for evaluation of immune cell infiltrate in stage iv colorectal cancer
CN114072676B (zh) 2019-06-03 2024-07-12 法国国家卫生及研究医学协会 调节治疗方案的方法
CA3151629A1 (en) 2019-11-07 2021-05-14 Laura E. BENJAMIN Classification of tumor microenvironments
CN111551546B (zh) * 2020-06-01 2023-01-03 南京瑟斯检测科技有限公司 一种基于光学微腔结构超材料的免疫组化便捷检测方法
JP7741831B2 (ja) * 2020-06-30 2025-09-18 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 術前補助療法及び根治手術後の固形がんを患っている患者の再発及び/又は死亡のリスクを予測するための方法
CN115997123A (zh) 2020-06-30 2023-04-21 国家医疗保健研究所 用于预测实体癌患者在术前辅助治疗后复发和/或死亡风险的方法
TWI838687B (zh) * 2021-01-30 2024-04-11 奇美醫療財團法人奇美醫院 評估腫瘤標本免疫狀態的方法
CN113092202A (zh) * 2021-03-25 2021-07-09 上海福君基因生物科技有限公司 一种胃癌预后预测装置
CN113515077A (zh) * 2021-04-23 2021-10-19 重庆德方信息技术有限公司 人体细胞染色过程监控系统及方法
WO2023018085A1 (ko) * 2021-08-10 2023-02-16 주식회사 루닛 병리 슬라이드 이미지와 관련된 정보를 출력하는 방법 및 장치
US20250035635A1 (en) 2022-03-17 2025-01-30 Institut National De La Sante Et De La Recherche Medicale Methods for predicting response to an immunotherapeutic treatment in a patient with a cancer
JP2026510999A (ja) 2023-03-21 2026-04-10 バイオグラフ 55,インク. Cd19/cd38多重特異性抗体
CN116646088B (zh) * 2023-07-27 2023-12-01 广东省人民医院 一种预测方法、装置、设备及介质

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2236268A1 (en) * 1995-11-30 1997-06-05 Chromavision Medical Systems, Inc. Method and apparatus for automated image analysis of biological specimens
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
AU2006333078B2 (en) * 2005-12-19 2012-03-01 Ventana Medical Systems, Inc. Automated lean methods in anatomical pathology
WO2010033508A1 (en) * 2008-09-16 2010-03-25 Historx, Inc. Reproducible quantification of biomarker expression
FR2964744B1 (fr) * 2010-09-10 2015-04-03 Univ Versailles St Quentin En Yvelines Test pronostic de l'evolution d'une tumeur solide par analyse d'images

Also Published As

Publication number Publication date
CN104541167A (zh) 2015-04-22
BR112014031143A2 (pt) 2017-08-08
IL235738A0 (en) 2015-01-29
BR112014031143B1 (pt) 2022-03-03
IL235738B (en) 2019-02-28
EP2861986B1 (en) 2021-11-10
ES2902879T3 (es) 2022-03-30
WO2013186374A1 (en) 2013-12-19
JP2015525349A (ja) 2015-09-03
DE13731071T1 (de) 2016-08-18
CN104541167B (zh) 2018-05-01
AU2013276470A1 (en) 2014-11-27
JP6449765B2 (ja) 2019-01-09
KR20150023760A (ko) 2015-03-05
US10317408B2 (en) 2019-06-11
AU2013276470B2 (en) 2018-06-07
BR112014031143B8 (pt) 2022-11-22
KR102179848B1 (ko) 2020-11-17
US20150153349A1 (en) 2015-06-04
CA2873278C (en) 2021-10-26
CA2873278A1 (en) 2013-12-19
EP2861986A1 (en) 2015-04-22

Similar Documents

Publication Publication Date Title
SG11201408107RA (en) Method for quantifying immune cells in tumoral tissues and its applications
SG11201903958SA (en) Intuitive occluded object indicator
SG11201809317VA (en) Methods for classifying patients with a solid cancer
SG11201809294RA (en) Systems and methods for sensor data analysis through machine learning
SG11201908865WA (en) Apparatus and method for absolute quantification of biomarkers for solid tumor diagnosis
SG11201407668XA (en) Method and device for detecting an analyte in a body fluid
SG11201908127WA (en) Method for producing multispecific antibodies
SG11201408385TA (en) Methods of detecting diseases or conditions
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11202000073XA (en) Anti-cd8 antibodies and uses thereof
SG11201406903SA (en) Cell culture compositions and methods for polypeptide production
SG11201803666WA (en) Single image detection
SG11201901611YA (en) Methods for the identification, targeting and isolation of human dendritic cell (dc) precursors "pre-dc" and their uses thereof
SG11201908847TA (en) Apparatuses, systems and methods for imaging flow cytometry
SG11201805532XA (en) Multivalent and multispecific 41bb-binding fusion proteins
SG11201903032SA (en) Methods and compositions related to nk cell and anti-pdl1 cancer therapies
SG11201908240YA (en) Methods for evaluating tumor cell spheroids using 3d microfluidic cell culture device
SG11201804144UA (en) High-throughput imaging-based methods for predicting cell-type-specific toxicity of xenobiotics with diverse chemical structures
SG11201908767QA (en) Method for accurate diagnosis of a disease targeting biomarkers in liquid biopsy
SG11201407459QA (en) System and method for predicting the immunogenicity of a peptide
SG11201408251SA (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
SG11201906413XA (en) Exposure apparatus
SG11201408652SA (en) Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
SG11201407294UA (en) Contamination identification system
SG11201906238TA (en) Split sector level sweep using beamforming refinement frames